AU
UK
CA
NZ
IND
US
Last update at 2026-06-05T15:35:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -12.65400M | -8.35400M | -5.92900M | -3.64000M | -0.71600M |
| Minority interest | - | - | - | - | - |
| Net income | -12.33300M | -7.66500M | -5.15000M | -3.23500M | -0.71900M |
| Selling general administrative | 1.41M | 1.26M | 2.71M | 1.73M | 0.52M |
| Selling and marketing expenses | 0.35M | 0.28M | 0.24M | 0.13M | 0.14M |
| Gross profit | 0.63M | 0.34M | 0.24M | 0.27M | 0.27M |
| Reconciled depreciation | 0.93M | 0.71M | 0.43M | 0.32M | 0.28M |
| Ebit | -11.90200M | -8.05200M | -5.84000M | -3.52700M | -0.62200M |
| Ebitda | -10.96900M | -7.34300M | -5.40900M | -3.20700M | -0.34500M |
| Depreciation and amortization | 0.93M | 0.71M | 0.43M | 0.32M | 0.28M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -12.04200M | -8.05200M | -5.84000M | -3.52700M | -0.62200M |
| Other operating expenses | 12.97M | 8.56M | 6.11M | 3.87M | 1.08M |
| Interest expense | 0.75M | 0.30M | 0.09M | 0.11M | 0.09M |
| Tax provision | -0.32100M | -0.68900M | -0.77900M | -0.40500M | 0.00300M |
| Interest income | 0.14M | 0.00000M | - | - | - |
| Net interest income | -0.61200M | -0.30200M | -0.08900M | -0.11300M | -0.09400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.32100M | -0.68900M | -0.77900M | -0.40500M | 0.00300M |
| Total revenue | 0.93M | 0.51M | 0.27M | 0.34M | 0.46M |
| Total operating expenses | 12.67M | 8.39M | 6.08M | 3.80M | 0.90M |
| Cost of revenue | 0.30M | 0.17M | 0.03M | 0.07M | 0.19M |
| Total other income expense net | -0.61200M | -0.30200M | -0.08900M | -0.11300M | -0.09400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -12.33300M | -7.66500M | -5.15000M | -3.23500M | -0.71900M |
| Net income applicable to common shares | - | - | - | -3.23500M | -0.71900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 44.73M | 11.92M | 11.69M | 14.70M | 17.81M |
| Intangible assets | 3.48M | 2.67M | 2.12M | 1.27M | 0.79M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.63M | 1.51M | 1.36M | 0.85M | 0.34M |
| Total liab | 18.35M | 12.41M | 4.57M | 3.01M | 2.35M |
| Total stockholder equity | 26.38M | -0.49200M | 7.12M | 11.70M | 15.46M |
| Deferred long term liab | - | - | - | 1.10M | 0.68M |
| Other current liab | 1.38M | 1.19M | 0.61M | 0.74M | 0.30M |
| Common stock | 13.77M | 11.13M | 11.13M | 11.13M | 11.13M |
| Capital stock | 13.77M | 11.13M | 11.13M | 11.13M | 11.13M |
| Retained earnings | -38.72300M | -26.39000M | -18.72500M | -13.57500M | -10.34000M |
| Other liab | - | - | - | 0.16M | 0.24M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | 0.03M | 0.72M |
| Cash | 34.60M | 3.07M | 4.35M | 9.59M | 15.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3.27M | 2.28M | 1.52M | 1.52M | 0.81M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -19.38800M | 7.39M | -1.00100M | -7.82800M | -13.28400M |
| Short term debt | 0.19M | 0.39M | 0.41M | 0.43M | 0.42M |
| Short long term debt | 0.15M | 0.26M | 0.32M | 0.36M | 0.35M |
| Short long term debt total | 15.22M | 10.46M | 3.35M | 1.76M | 1.72M |
| Other stockholder equity | 37.25M | 1.39M | 14.71M | 14.14M | 14.67M |
| Property plant equipment | - | - | - | 2.76M | 1.48M |
| Total current assets | 36.89M | 5.02M | 5.90M | 10.64M | 15.51M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 10.42M | 15.36M |
| Short term investments | 0.23M | 0.24M | - | - | - |
| Net receivables | 0.28M | 0.11M | 0.05M | 0.05M | 0.04M |
| Long term debt | 14.29M | 9.30M | 2.41M | 0.86M | 1.23M |
| Inventory | 0.37M | 0.33M | 0.13M | 0.16M | 0.13M |
| Accounts payable | 1.69M | 0.69M | 0.49M | 0.35M | 0.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 14.08M | 13.37M | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.03M | 0.03M | 0.04M | 0.03M | 0.03M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 7.84M | 6.90M | 5.79M | 4.06M | 2.30M |
| Capital lease obligations | 0.78M | 0.89M | 0.61M | 0.54M | 0.14M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -1.57100M | -1.49000M | -1.94100M | -1.51200M | 1.45M |
| Change to liabilities | - | - | - | 0.61M | -0.87600M |
| Total cashflows from investing activities | -1.57100M | -1.49000M | - | -1.51200M | 1.45M |
| Net borrowings | 4.81M | 6.58M | - | -0.39100M | -1.08300M |
| Total cash from financing activities | 43.87M | 6.42M | 1.24M | -0.46700M | 14.43M |
| Change to operating activities | - | - | - | - | - |
| Net income | -12.33300M | -7.66500M | -5.15000M | -3.23500M | -0.71900M |
| Change in cash | 31.54M | -1.28200M | -5.23500M | -5.41500M | 14.92M |
| Begin period cash flow | 3.07M | 4.35M | 9.59M | 15.00M | 0.08M |
| End period cash flow | 34.60M | 3.07M | 4.35M | 9.59M | 15.00M |
| Total cash from operating activities | -10.74400M | -6.17800M | -4.70400M | -2.74000M | -1.02200M |
| Issuance of capital stock | 39.18M | 0.00200M | - | - | 15.63M |
| Depreciation | 0.93M | 0.71M | 0.43M | 0.32M | 0.28M |
| Other cashflows from investing activities | -0.87400M | -0.61900M | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.04900M | -0.20200M | 0.03M | -0.03400M | -0.02400M |
| Change to account receivables | -0.07600M | -0.10900M | - | -0.12600M | 0.09M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -0.12900M | -0.16100M | -1.94100M | -0.13600M | -1.19900M |
| Change to netincome | - | - | - | -0.28000M | 0.23M |
| Capital expenditures | 1.57M | 1.49M | 1.94M | 1.51M | 0.85M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.62M | 0.38M | 0.17M | 0.46M | -0.80900M |
| Stock based compensation | - | 0.22M | - | - | - |
| Other non cash items | 0.03M | 0.39M | -0.15300M | -0.28000M | 0.23M |
| Free cash flow | -12.31500M | -7.66800M | -6.64500M | -4.25200M | -1.87100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| 4BB 4BASEBIO UK SOCIETAS |
-32.5 5.94% | 515.00 | - | - | 46.11 | 3.95 | 31.23 | -18.9246 |
| GNS Genus PLC |
- -% | 2274.00 | 36.08 | 26.18 | 2.53 | 3.46 | 2.92 | 15.38 |
| ONT Oxford Nanopore Technologies Ltd |
-9.7 6.93% | 130.30 | - | - | 4.71 | 2.50 | 4.23 | -8.8899 |
| OXB Oxford BioMedica PLC |
30.00 5.00% | 630.00 | - | 208.33 | 4.05 | 7.60 | 4.42 | 308.96 |
| AVCT Avacta Group PLC |
1.50 2.14% | 71.50 | - | - | 2849.46 | 1929.84 | 2525.51 | -12.0368 |
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccines and therapeutics; and oeDNA, or open ended DNA, a linear, double stranded DNA product ideal for genome editing. It also provides osDNA, or open stabilized DNA, a product incorporating nucleotide modifications within the DNA backbone enables tuning of the immunostimulatory properties of the construct for DNA vaccine applications; and The Hermes, a proprietary delivery platform for nucleic acid and protein payloads appears to offer a thermo-stable alternative to traditional lipid based delivery systems. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
25 Norman Way, Cambridge, United Kingdom, CB24 5QE
| Name | Title | Year Born |
|---|---|---|
| Dr. Heikki Lanckriet Ph.D. | CEO, Chief Scientific Officer & Exec. Director | 1977 |
| Mr. David Roth | CFO, Company Sec. & Exec. Director | NA |
| Mr. Mark Cooper | Head of Manufacturing | NA |
| Mr. David Roth | CFO, Company Secretary & Executive Director | 1967 |
| Dr. Heikki Lanckriet Ph.D. | Chief Scientific Officer & Executive Director | 1977 |
| Dr. Manja Hermina Elisabeth Maria Boerman Ph.D. | Executive Chair of the Board | 1966 |
| Dr. Amy Jo Walker | CEO & Director | 1993 |
| Mr. Scott Lorimer | Chief Operating Officer | NA |
| Ms. Jennifer Gelman | Vice President of Marketing | NA |
| Ms. Christine Wolosin | Chief Commercial Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...